Option Care Health (OPCH) Q4 2025 earnings review
Top-Line Deceleration and a Massive Cash Flow Miss
Option Care Health delivered a mixed end to 2025. While full-year revenue grew an impressive 13%, the trajectory is clearly decelerating—from 16.3% YoY growth in Q1 down to 8.8% in Q4. More alarmingly, the volume growth is not translating to the bottom line, with Q4 Net Income reversing to a 2.7% decline. Margins remain under intense pressure from the Stelara biosimilar transition and an unfavorable shift toward lower-margin therapies. Furthermore, despite management's prior confidence in generating 'at least $320M' in operating cash flow, actual FY25 OCF came in at just $258.4M due to ballooning working capital. FY26 guidance confirms the slowdown, projecting revenue growth of just ~4.4% at the midpoint. To offset the operational deceleration, the board has authorized a massive new $1.0B share repurchase program.
🐂 Bull Case
The company repurchased $307M of stock in FY25 and just upsized its authorization to $1.0B in January 2026. This massive buyback program provides a strong floor for the stock and EPS support while the company navigates biosimilar headwinds.
The structural shift of higher-acuity care moving from expensive hospitals to home and ambulatory settings continues. OPCH's scale (190 locations, 750 infusion chairs, 5,000 clinicians) positions it perfectly as payers force site-of-care redirection to manage their medical loss ratios.
🐻 Bear Case
The transition to Stelara biosimilars under the Inflation Reduction Act is a massive drag. Management explicitly guided that these dynamics will create a 400 basis point headwind to total revenue growth in 2026.
The company severely missed its own $320M operating cash flow target, delivering only $258.4M in FY25. This was driven by a $81.5M drain from inventories and a $54.6M drag from accounts receivable, indicating potential collection issues or supply chain inefficiencies.
⚖️ Verdict: ⚪
Neutral. The core business volume remains healthy and the $1B buyback is a strong signal, but the steep deceleration in growth, the severe cash flow miss, and the ongoing margin compression from biosimilars make it difficult to be aggressively bullish until the Stelara headwind is fully lapped.
Key Themes
Working Capital Spikes Contradict Cash Flow Narrative
Throughout 2025, management repeatedly touted their 'robust cash flow generation,' explicitly guiding to 'at least $320 million' in operating cash flow as late as Q3. However, FY25 actuals came in at just $258.4M—a miss of over $60M. A review of the cash flow statement reveals the culprits: an $81.5M headwind from swelling inventories and a $54.6M drag from accounts receivable. This data point contradicts the operational efficiency narrative and requires immediate monitoring for potential bad debt or bloated channel inventory.
The Stelara Biosimilar Cliff (Macro Impact)
The adoption of lower-priced Stelara biosimilars, driven by the Inflation Reduction Act (IRA) and PBM initiatives, is crushing gross profit. Management confirmed a full-year 2025 GP hit near $70 million. For FY26, the pain continues: Stelara dynamics are projected to create a massive 400 basis point headwind to total revenue growth, compressing margins as reference pricing steps down.
Market Share Gains in Acute Therapies
A bright spot has been OPCH's ability to capitalize on competitor retrenchment in the acute therapy market. By leveraging their Naven Health internal nursing agency (which conducted almost 50,000 visits in Q1 alone) and improved IV bag supply, the company drove mid-teens growth in acute therapies through most of 2025, significantly outpacing the low-single-digit macro market growth.
Lapping Favorable Comps
The outsized mid-teens growth seen in the acute portfolio during H1 2025 was largely driven by a 'growth surge' from market disruption and competitor exits. As OPCH laps these gains entering 2026, the growth rate is mathematically forced into a steep deceleration, shifting the burden back to core organic volume expansion.
Payer 'Site of Care' Redirection
As health plans face intense Medical Loss Ratio (MLR) pressure, they are aggressively directing members out of hospital settings. OPCH's growing footprint of 190 locations and 750 infusion chairs acts as a primary beneficiary. In early 2025, over one-third of nursing visits were conducted in these dedicated centers, up from historical averages, driving a 20%+ uplift in nurse productivity.
Palantir AI and Advanced Practitioner Rollout
To offset gross margin pressure, OPCH is heavily investing in technology and clinical efficiency. The company is deploying Palantir's AI solutions and Robotic Process Automation (RPA) to accelerate revenue cycle management and patient onboarding. Additionally, learnings from the Intramed Plus acquisition are being used to scale an 'Advanced Practitioner Model', allowing the company to treat higher-acuity patients (like oncology and Alzheimer's) that previously required hospital care.
Other KPIs
Decelerating. Q4 gross margin compressed to 19.3%, down from 19.9% a year ago. The compression is driven entirely by therapy mix—specifically the negative impact of Stelara biosimilar pricing and a shift toward fast-growing but lower-margin rare and orphan drugs.
Stable sequentially, but up 4.5% YoY in Q4. However, total SG&A for the year grew 8.3% to $682.5M. Management points to integration costs from the Intramed Plus acquisition and investments in their Palantir AI initiatives as the primary drivers of this overhead expansion.
Guidance
Decelerating. The $5.9B midpoint implies just 4.4% YoY growth, a sharp slowdown from the 13.0% growth achieved in FY25. Management explicitly cited a 400 basis point headwind from Stelara pricing dynamics as the primary drag.
Decelerating. The $492.5M midpoint implies 4.5% YoY growth, down from 6.2% growth in FY25. This indicates that while the company is managing to preserve margin percentages, absolute profit growth is slowing in tandem with the top line.
Stable. The $1.87 midpoint implies 8.7% growth. The fact that EPS is growing roughly twice as fast as Revenue and EBITDA highlights how heavily OPCH is relying on its aggressive share repurchase program to engineer per-share earnings growth.
Accelerating/Rebounding. After printing a severely disappointing $258.4M in FY25 due to working capital blowouts, management expects a sharp recovery. Achieving this will require unwinding the excessive inventory build and fixing the accounts receivable drag seen in late 2025.
Key Questions
Working Capital & Cash Flow Miss
Operating cash flow missed your $320M target by over $60M, heavily impacted by an $81M increase in inventory and a $54M increase in A/R. What specifically drove this working capital bloat in Q4, and what gives you confidence in the $340M target for FY26?
Stelara Margin Floor
You guided for a 400 basis point revenue headwind from Stelara in 2026. Given the continued step-downs in IRA reference pricing, at what point during FY26 do you expect the margin compression from this specific drug to fully bottom out?
Capital Allocation Shift
The Board just authorized a massive $1.0B share repurchase program. Does this indicate a pivot away from M&A due to high private market multiples, or simply a belief that OPCH shares are mispriced given the temporary biosimilar headwinds?
Acute Care Growth Normalization
As we lap the competitor exits that fueled the mid-teens acute care growth in early 2025, what is the organic 'steady-state' growth expectation for the acute portfolio going forward?